Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives

ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces its CEO and Founder Kathy Lee-Sepsick has met with several members of Congress to discuss the current women’s healthcare landscape. Further, Lee-Sepsick is raising awareness of Femasys and the status of its reproductive products in light of the recently announced women’s health initiative from the White House. In mid-March President Biden released an executive order, which calls for a $200M investment in research for women’s health and a coordinated approach from more than 20 federal government agencies in addition to the $100M investment announced in November 2023.

“Women’s health remain vastly underserved and underfunded but we are encouraged by the interest our solutions have received during recent meetings with members of Congress,” remarked Lee-Sepsick. “I am proud to be a female-founder and to lead Femasys as we develop revolutionary technologies that provide a continuum of care that are safe, affordable and accessible to women. It is our goal to empower women throughout their reproductive journey by delivering innovative options to meet their needs.”

Femasys provides minimally-invasive solutions that share delivery platforms. It has four commercially available products: FemaSeed – FDA-cleared, intratubal insemination, FemVue – contrast-generating device, FemCath – selective delivery catheter, and FemCerv – endocervical tissue sampler. And its current lead product candidate in late-stage clinical development is FemBloc – permanent birth control.

The Company recently announced topline data from its FemaSeed pivotal trial, which investigated FemaSeed in women with a variety of infertility factors with the primary efficacy analysis focused on the male factor infertility. FemaSeed demonstrated 24% of women became pregnant after FemaSeed with male factor (1 million to 20 million total motile sperm count (TMSC)). Although permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure.